ArticleCardiovascular endocrinology & metabolism2025
Utilizing natriuretic peptides for predicting heart failure risk following myocardial infarction.
Article in Cardiovascular endocrinology & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From acute diagnosis to longitudinal risk stratification: a paradigm shift in the clinical role of cardiac biomarkers.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Mongolia, ischemic heart disease, specifically acute myocardial infarction (AMI), is a significant etiology of chronic heart failure (HF). Therefore, early recognition of the risk of HF following AMI is critically important for improving patient management. This study aimed to assess the N-terminal pro-B-type natriuretic peptide (NT-proBNP) as an early detection and prognosis of asymptomatic left ventricular (LV) dysfunction following AMI. Methods: Patients diagnosed with AMI and in the absence of symptoms or signs of HF were prospectively included. Clinical and echocardiographic data were collected at baseline, and NT-proBNP levels were measured at admission and discharge. Patients were divided into four distinct groups based on NT-proBNP level quartiles. The study endpoint was de-novo HF at 6 months after AMI. Results: A total of 120 patients with a mean age of 56.0 ± 9.2 years and 80.8% ( Conclusion: Incorporation of NT-proBNP measurement before discharge in AMI patients could enhance risk stratification, thereby supporting its integration into routine clinical evaluation for more efficient patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.